Meseclazone
Product Specifications
UNSPSC Description
Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/NSC297623.html
Solubility
10 mM in DMSO
Smiles
O=C1N(OC(C)C2)C2OC3=CC=C(Cl)C=C13
Molecular Weight
239.66
References & Citations
[1]Diamantis W, et al. Meseclazone, 5-chlorosalicylic acid and acetylsalicylic acid. Comparison of their effects on in vitro and ex vivo platelet aggregation. Thromb Haemost. 1978 Aug 31;40(1):24-36.|[2]Diamantis W, et al. Antagonism by meseclazone and other nonsteroidal anti-inflammatory drugs of bradykinin-induced bronchospasm. Pharmacology. 1982;24(4):243-7.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-U00157/Meseclazone-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-U00157/
Clinical Information
No Development Reported
CAS Number
29053-27-8
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6454776-01 0.2 mL
CASC5 (Protein CASC5, ALL1-fused gene from Chromosome 15q14 Protein, AF15q14, Bub-linking Kinetochore Protein, Blinkin, Cancer Susceptibility Candidate gene 5 Protein, Cancer/Testis antigen 29, CT29, Kinetochore-null Protein 1, Protein D40/AF15q14, CASC5,
Ask
View Details